Novartis AG ($NVS) Stock Forecast: Up 1.2% Today

What is Novartis AG?

Novartis International AG is a Swiss multinational pharmaceutical company that offers a variety of healthcare products, such as prescription drugs, generics, and eye care devices. The company has a global presence and is a significant player in the pharmaceutical industry.

Why is Novartis AG going up?

NVS stock is up 1.2% on Sep 30, 2025 14:41

• Novartis (NVS) displayed bullish movement today, potentially influenced by positive developments within its own pipeline or in the broader pharmaceutical sector.
• The recent decision by another company to halt a study on an obesity drug could have indirectly boosted Novartis, with investors viewing NVS as a more stable investment within the pharmaceutical industry.
• Investor attention may have shifted towards Novartis as a potential leader in the healthcare sector, following setbacks experienced by a competitor, potentially driving the bullish performance of NVS stock today.

NVS Price Chart

NVS Technical Analysis

NVS News

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch - Eli Lilly ( NYSE:LLY )

On Wednesday, Eli Lilly & Co. ( NYSE: LLY ) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The company cited strategic business reasons for halting the trial, though a parallel study in non-diabetic obesity ...

https://www.benzinga.com/markets/large-cap/25/09/47869316/eli-lilly-ends-bimagrumab-obesity-study-weeks-after-launch

Trending Today

Novartis AG Price History

29.09.2024 - NVS Stock was down 3.5%

• NVS experienced a bearish movement today despite being included in a list of stocks likely to gain on a potential Q3 earnings beat.
• The mention of Novartis alongside other companies may have caused uncertainty among investors, leading to a sell-off.
• The anticipation of earnings results tomorrow could have also contributed to profit-taking by traders, resulting in the bearish trend for NVS.
• Investors might be reevaluating their positions in NVS amidst the broader market volatility, leading to the downward movement in the stock price.

16.03.2024 - NVS Stock was down 1.7%

• Positive data regarding Fabhalta for a rare kidney disease may have been eclipsed by market concerns or uncertainties.
• Despite encouraging results from a phase III study, investors possibly reacted unfavorably to other influencing factors affecting Novartis.
• The recent acquisition of Alpine Immune Sciences by Vertex Pharmaceuticals might have diverted investor attention from Novartis, leading to the bearish market movement.
• The growing market presence of a Humira biosimilar, indirectly connected to Novartis, could have impacted investor sentiment towards the pharmaceutical industry as a whole, playing a role in NVS's decline.

30.08.2025 - NVS Stock was up 1.2%

• Novartis (NVS) displayed bullish movement today, potentially influenced by positive developments within its own pipeline or in the broader pharmaceutical sector.
• The recent decision by another company to halt a study on an obesity drug could have indirectly boosted Novartis, with investors viewing NVS as a more stable investment within the pharmaceutical industry.
• Investor attention may have shifted towards Novartis as a potential leader in the healthcare sector, following setbacks experienced by a competitor, potentially driving the bullish performance of NVS stock today.